EFCG says EU gets too many APIs from foreign plants; Biocon launching Herceptin biosimilar;

> The European Fine Chemicals Group (EFCG) says the EU reliance on active pharmaceutical ingredients manufactured outside of the EU remains a concern. Story

> India's Biocon expects to launch in two weeks a biosimilar of Roche's ($RHHBY) Herceptin cancer drug in its home country. Story

> Reaction Biology Corp., a manufacturer of recombinant human epigenetic proteins has an agreement with Cisbio Bioassays to distribute its epigenetic proteins. Report

> With the signing of the fiscal 2014 budget, the FDA will have additional resources to expand inspections overseas. Story

And Finally... Eli Lilly ($LLY) says it has launched in India its Humapen Savvio, an insulin pen that can be used for up to 6 years. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.